Investigational Drug Information for JNJ-70033093
What is the development status for investigational drug JNJ-70033093?
JNJ-70033093 is an investigational drug.
There have been 12 clinical trials for JNJ-70033093.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 8th 2023.
The most common disease conditions in clinical trials are Ischemia, Cerebral Infarction, and Syndrome. The leading clinical trial sponsors are Janssen Research & Development, LLC, Bristol-Myers Squibb, and Janssen Pharmaceutica N.V., Belgium.
There are eleven US patents protecting this investigational drug and one hundred and twenty-six international patents.
Summary for JNJ-70033093
| US Patents | 11 |
| International Patents | 126 |
| US Patent Applications | 46 |
| WIPO Patent Applications | 30 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2023-03-08) |
| Vendors | 33 |
Recent Clinical Trials for JNJ-70033093
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome | Janssen Research & Development, LLC | Phase 3 |
| A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Bristol Myers Squibb Company (BMS) | Phase 3 |
| A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Research & Development, LLC | Phase 3 |
Clinical Trial Summary for JNJ-70033093
Top disease conditions for JNJ-70033093
Top clinical trial sponsors for JNJ-70033093
US Patents for JNJ-70033093
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| JNJ-70033093 | ⤷ Start Trial | Pyrimidinones as factor XIa inhibitors | Bristol Myers Squibb Co | ⤷ Start Trial |
| JNJ-70033093 | ⤷ Start Trial | Pyrimidinones as factor XIA inhibitors | Bristol Myers Squibb Co | ⤷ Start Trial |
| JNJ-70033093 | ⤷ Start Trial | Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane | Boulder Bioscience LLC | ⤷ Start Trial |
| JNJ-70033093 | ⤷ Start Trial | Substituted S-alaninate derivatives | Bayer AG | ⤷ Start Trial |
| JNJ-70033093 | ⤷ Start Trial | Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane | Boulder Bioscience LLC | ⤷ Start Trial |
| JNJ-70033093 | ⤷ Start Trial | Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof | Bristol Myers Squibb Co | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for JNJ-70033093
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| JNJ-70033093 | Argentina | AR099227 | 2034-01-31 | ⤷ Start Trial |
| JNJ-70033093 | Argentina | AR099550 | 2034-01-31 | ⤷ Start Trial |
| JNJ-70033093 | Argentina | AR101367 | 2034-01-31 | ⤷ Start Trial |
| JNJ-70033093 | Australia | AU2015210904 | 2034-01-31 | ⤷ Start Trial |
| JNJ-70033093 | Australia | AU2015324530 | 2034-01-31 | ⤷ Start Trial |
| JNJ-70033093 | Australia | AU2019216617 | 2034-01-31 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
